Quanta Therapeutics

Conformational Blockade of RAS in Cancer

United States · $50.0M raised

Business Model
B2B
Total Funding
$50.0M
Last Round
$50.0M Series DMay 2023
Rounds
2

About

Quanta Therapeutics is a private biopharmaceutical company pioneering allosteric modulation to restore conformational control of active RAS signaling at the cell membrane and treat RAS-driven cancers. Using a proprietary Second Harmonic Generation platform, the company discovers oral small molecules against previously undruggable KRAS mutations, with a pipeline that includes QTX3034, a G12D-preferring multi-KRAS inhibitor in Phase 1 trials for pancreatic, colorectal, and endometrial cancers. Quanta's programs target a broad spectrum of RAS-driven tumors of the colon, pancreas, and lung, with potential as monotherapies and combination therapies.

Summary

Quanta Therapeutics is a Biotech company based in United States. It has raised $50.0M in total across 2 rounds, most recently a $50.0M Series D round in May 2023. Investors include Longitude Capital and BVF Partners.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series DSeries DMay 2023
$50.0M

Sign up to see all 2 events

Funding: Venture Round through Series D. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Quanta Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/quanta-therapeutics"><img src="https://indexed.vc/api/badge/company/quanta-therapeutics" alt="Quanta Therapeutics on Indexed.vc" width="260" height="76" /></a>